Navigation Links
The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers

SAN MARINO, Calif., June 9 /PRNewswire/ -- Epeius Biotechnologies' Rexin-G is the world's smallest hero ( Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside. Guided by nature's own disease-seeking factors (i.e., pathotropic targeting), armed with a powerful tumor-killing designer gene, and trained in the art of efficient gene delivery over aeons of evolutionary engineering, these tiny therapeutic particles represent a new paradigm in drug delivery and a new class of anti-cancer agents that exhibit profound and unprecedented single-agent efficacy in many cancers.

By selectively targeting cancers and their associated blood supply, while sparing normal cells and healthy tissues, these tiny nano-particles are inherently "smart." In performing a vital cancer surveillance function, they are uniformly "vigilant." By taking on a broad spectrum of cancers that are determined to be refractory to standard chemotherapy (i.e., ineffectual apothecary), they are exceedingly "valiant." By reducing the cancer patient's body burden and extending overall survival, they are truly "heroic." In a manner of speaking, these tiny nano-particles may well be the smallest heroes in all the world.

These "heroic" qualities are now embodied in the tumor-targeted anti-cancer agent, Rexin-G, developed by Epeius Biotechnologies. Rexin-G is currently approved for the treatment of all solid chemo-resistant tumors in the Republic of the Philippines. It has recently been granted Orphan Drug Status and market protections for three separate cancer indications by the U.S. FDA. Ongoing clinical trials in the U.S. have established the thresholds for bioactivity and the dose-dependent efficacy of Rexin-G, as well as its overall safety and lack of any dose-limiting toxicity. Recent advanced and confirmatory clinical trials in the U.S. have demonstrated single-agent efficacy, which included both progression-free survival and overall survival. Not bad, for the world's smallest unsung hero.

For further information about Rexin-G, high-performance targeting technologies, and/or new products in development, see For further information about current clinical trials, contact Erlinda M. Gordon, M.D., at


This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tickets for Brand New Exhibition Body Worlds & The Mirror of Time on Sale 18 July
2. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
3. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. Signostics Receives FDA Clearance for Worlds Smallest Ultrasound Product
6. Stanford writes in worlds smallest letters
7. Smallest ever quantum dots bring real world applications closer
8. Detecting smallest contaminations on semiconductors with aid of synchrotron radiation
9. Naviscans PEM Flex(TM) Detects Smallest Cancers Better Compared to MRI in an Independent Study
10. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
11. Graphene used to create worlds smallest transistor
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, ... (ECNR) in Vienna, Austria to ... Congress of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ... of its Internet-delivered NovaVision Therapy Suite at the 3rd ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, ... and rodent control solutions , Bird Free, ... works across all sensory modalities including visual, smell, taste and touch, enabling safe, effective ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... -- 2 nouvelles études permettent d , ... entre les souches bactériennes retrouvées dans la plaque ... . Ces recherches  ouvrent une nouvelle voie ... efficace de l,un des problèmes de santé les ...    --> 2 nouvelles études permettent d ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
Breaking Biology News(10 mins):